Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/07/22
Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate CancerGlobeNewsWire • 01/20/22
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell LymphomaGlobeNewsWire • 01/04/22
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021GlobeNewsWire • 12/13/21
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual MeetingGlobeNewsWire • 11/15/21
Week 46 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 11/13/21
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare ConferenceGlobeNewsWire • 11/09/21
Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/21
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/04/21
Oncternal Therapeutics Joins Karolinska Institutet's NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer ImmunotherapiesGlobeNewsWire • 11/03/21
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory BoardGlobeNewsWire • 11/02/21
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial ResultsGlobeNewsWire • 10/29/21
Will Oncternal Therapeutics (ONCT) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/27/21
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets GlobeNewsWire • 10/05/21
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/01/21
Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality AssuranceGlobeNewsWire • 09/01/21
Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/09/21